Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Guangzhou Baiyunshan Pharmaceutical Holdings Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 2/6
Guangzhou Baiyunshan Pharmaceutical Holdings yıllık ortalama 7.7% oranında kazançlarını artırırken, Healthcare sektöründe kazançlar growing at 11.7% annual. Gelirler growing yılda ortalama 4.7% oranında artmaktadır. Guangzhou Baiyunshan Pharmaceutical Holdings'in özkaynak karlılığı 10.5% ve net marjı 5%'dir.
Anahtar bilgiler
7.7%
Kazanç büyüme oranı
7.7%
EPS büyüme oranı
Healthcare Sektör Büyümesi | 11.3% |
Gelir büyüme oranı | 4.7% |
Özkaynak getirisi | 10.5% |
Net Marj | 5.0% |
Sonraki Kazanç Güncellemesi | 26 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Here's What's Concerning About Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns On Capital
Sep 25Earnings Report: Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Missed Revenue Estimates By 8.1%
Sep 04A Look At The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Jul 15Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Appear To Be Weighed Down
Jun 26Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Increasing Its Dividend To CN¥0.8227
Jun 03The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Gelir ve Gider Dağılımı
Guangzhou Baiyunshan Pharmaceutical Holdings nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 76,588 | 3,794 | 8,404 | 773 |
31 Mar 24 | 76,833 | 4,105 | 8,595 | 789 |
31 Dec 23 | 75,515 | 4,056 | 8,558 | 782 |
30 Sep 23 | 74,167 | 4,283 | 8,644 | 735 |
30 Jun 23 | 73,538 | 4,188 | 8,405 | 779 |
31 Mar 23 | 71,878 | 4,069 | 8,260 | 760 |
31 Dec 22 | 70,788 | 3,967 | 8,117 | 819 |
30 Sep 22 | 70,280 | 3,883 | 8,060 | 934 |
30 Jun 22 | 70,106 | 3,807 | 8,308 | 930 |
31 Mar 22 | 69,507 | 3,898 | 8,143 | 927 |
31 Dec 21 | 69,014 | 3,720 | 8,050 | 875 |
30 Sep 21 | 68,329 | 3,568 | 7,632 | 814 |
30 Jun 21 | 67,333 | 3,653 | 7,193 | 729 |
31 Mar 21 | 64,735 | 3,359 | 6,997 | 664 |
31 Dec 20 | 61,674 | 2,915 | 6,496 | 612 |
30 Sep 20 | 61,774 | 2,688 | 6,091 | 516 |
30 Jun 20 | 62,081 | 2,406 | 6,896 | 569 |
31 Mar 20 | 63,881 | 2,966 | 7,131 | 539 |
31 Dec 19 | 64,952 | 3,189 | 7,799 | 577 |
30 Sep 19 | 62,420 | 3,161 | 8,567 | 657 |
30 Jun 19 | 60,735 | 3,370 | 8,083 | 620 |
31 Mar 19 | 53,380 | 3,943 | 7,784 | 621 |
31 Dec 18 | 42,234 | 3,441 | 6,772 | 585 |
30 Sep 18 | 34,863 | 4,015 | 6,271 | 521 |
30 Jun 18 | 24,679 | 3,523 | 5,601 | 482 |
31 Mar 18 | 22,575 | 2,482 | 5,408 | 510 |
01 Jan 18 | 20,954 | 2,062 | 5,502 | 373 |
30 Sep 17 | 20,459 | 1,937 | 4,619 | 244 |
30 Jun 17 | 20,294 | 1,834 | 4,742 | 134 |
31 Mar 17 | 20,273 | 1,583 | 5,257 | 0 |
31 Dec 16 | 20,036 | 1,508 | 5,232 | 0 |
30 Sep 16 | 19,598 | 1,397 | 5,934 | 0 |
30 Jun 16 | 19,502 | 1,357 | 5,907 | 0 |
31 Mar 16 | 19,442 | 1,345 | 5,839 | 0 |
31 Dec 15 | 19,125 | 1,300 | 5,509 | 0 |
30 Sep 15 | 19,244 | 1,300 | 5,281 | 0 |
30 Jun 15 | 19,270 | 1,295 | 5,291 | 0 |
31 Mar 15 | 18,876 | 1,241 | 5,190 | 0 |
31 Dec 14 | 18,818 | 1,194 | 5,189 | 0 |
30 Sep 14 | 19,049 | 1,106 | 5,135 | 0 |
30 Jun 14 | 18,563 | 1,067 | 4,877 | 0 |
31 Mar 14 | 18,130 | 1,036 | 4,718 | 0 |
31 Dec 13 | 17,608 | 980 | 4,641 | 0 |
Kaliteli Kazançlar: 874 yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: 874 'nin mevcut net kar marjları (5%) geçen yılın (5.7%) değerinden daha düşüktür.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: 874 şirketinin kazancı son 5 yılda yılda 7.7% oranında arttı.
Büyüme Hızlandırma: 874 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.
Kazançlar vs. Sektör: 874 geçtiğimiz yıl negatif kazanç büyümesine ( -9.4% ) sahipti ve bu da onu Healthcare sektör ortalamasıyla ( -14.3% ) karşılaştırmayı zorlaştırıyordu.
Özkaynak Getirisi
Yüksek ROE: 874 'nin Özsermaye Getirisi ( 10.5% ) düşük olarak değerlendiriliyor.